The Trends of One-week First-line and Second-line Eradication Therapy for Helicobacter pylori Infection in Korea

被引:0
作者
Chung, Jun-Won [2 ]
Hyug-Lee, Gin [1 ]
Han, Jeung Hye [1 ]
Jeong, Jin-Yong [3 ]
Choi, Kwi-Sook [1 ]
Kim, Do Hoon [1 ]
Jung, Kee Wook [1 ]
Choi, Kee Don [1 ]
Song, Ho June [1 ]
Jung, Hwoon-Yong [1 ]
Kim, Jin-Ho [1 ]
机构
[1] Univ Ulsan, Dept Internal Med, Coll Med, Asan Med Ctr, Seoul 138736, South Korea
[2] Gachon Univ, Gil Med Ctr, Dept Internal Med, Inchon, South Korea
[3] Univ Ulsan, Asan Inst Life Sci, Coll Med, Asan Med Ctr, Seoul 138736, South Korea
关键词
Helicobacter pylori; Triple therapy; Clarithromycin; Bismuth; PROTON PUMP INHIBITOR; TRIPLE THERAPY; ANTIMICROBIAL RESISTANCE; ANTIBIOTIC-RESISTANCE; METAANALYSIS; MANAGEMENT; QUADRUPLE; CLARITHROMYCIN; EFFICACY; FAILURE;
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Increasing levels of bacterial antibiotic resistance raise the need to assess the eradication efficiency of Helicobacter pylori. The aim of this study was to evaluate 7-year changes in efficacy of one-week first line and second line therapies in Helicobacter pylori eradication rates in Korea. Methodology: From 2001 to 2007, 4,198 Helicobacter pylori-positive patients received first-line therapy (proton pump inhibitor, amoxicillin 1,000 mg b.i.d., and clarithromycin 500 mg b.i.d.). Four hundred ninety patients received second-line therapy (proton pump inhibitor twelve hourly, metronidazole 500 mg t.i.d., tetracycline 500 mg q.i.d., and bismuth 300 mg q.i.d.). A C-13-urea breath test was used to determine the eradication rate. Results: The eradication rates of first-line therapy were 81.3%, 83.7%, 80.1%, 80.7%, 82.0%, 75.9%, and 77.5% from 2001 to 2007, with a decreasing trend (p < 0.01). The eradication rate of second-line therapy was 77.3%, 86.2%, 95.6%, 95.9%, 89.6%, 83.2%, and 86.4% from 2001 to 2007 without decreasing trend (p=0.26). Conclusions: The eradication rate of first-line therapy has decreased in the last 7 years while that of second-line therapy has remained the same. A new strategy is required to improve the first-line therapy for Helicobacter pylori eradication in Korea.
引用
收藏
页码:246 / 250
页数:5
相关论文
共 36 条
[1]  
Bang So Young, 2007, Korean J Gastroenterol, V50, P356
[2]   Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection [J].
Cheon, JH ;
Kim, N ;
Lee, DH ;
Kim, JM ;
Kim, JS ;
Jung, HC ;
Song, IS .
HELICOBACTER, 2006, 11 (01) :46-51
[3]   American college of gastroenterology guideline on the management of Helicobacter pylori infection [J].
Chey, William D. ;
Wong, Benjamin C. Y. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 (08) :1808-1825
[4]  
Choi Woo Hyuk, 2008, Korean J Gastroenterol, V51, P280
[5]  
Choi You Sik, 2006, Korean J Gastroenterol, V48, P156
[6]  
CHOUNG RS, 2006, J GASTROENTEROL, V47, P131
[7]  
Chung WC, 2003, KOREAN J GASTROENTER, V41, P1
[8]   Changing pattern of antimicrobial resistance of Helicobacter pylori in Korean patients with peptic ulcer diseases [J].
Eun, CS ;
Han, DS ;
Park, JY ;
Jeon, YC ;
Hahm, JS ;
Kim, KS ;
Kang, JO .
JOURNAL OF GASTROENTEROLOGY, 2003, 38 (05) :436-441
[9]   Meta-analysis:: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori [J].
Fischbach, L. ;
Evans, E. L. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (03) :343-357
[10]   Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H-pylori [J].
Furuta, T. ;
Shirai, N. ;
Kodaira, M. ;
Sugimoto, M. ;
Nogaki, A. ;
Kuriyama, S. ;
Iwaizumi, M. ;
Yamade, M. ;
Terakawa, I. ;
Ohashi, K. ;
Ishizaki, T. ;
Hishida, A. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (04) :521-528